Background: An increased incidence of fungal infections, both invasive and superficial, has been witnessed over\r\nthe last two decades. Candida species seem to be the main etiology of nosocomial fungal infections worldwide\r\nwith Candida albicans, which is commensal in healthy individuals, accounting for the majority of invasive Candida\r\ninfections with about 30-40% of mortality.\r\nResults: New aromatic and heterocyclic esters 5a-k of 1-aryl-3-(1H-imidazol-1-yl)propan-1-ols 4a-d were successfully\r\nsynthesized and evaluated for their anti-Candida potential. Compound 5a emerged as the most active congener\r\namong the newly synthesized compounds 5a-k with MIC value of 0.0833 �µmol/mL as compared with fluconazole\r\n(MIC value >1.6325 �µmol/mL). Additionally, molecular modeling studies were conducted on a set of anti-Candida\r\nalbicans compounds.\r\nConclusion: The newly synthesized esters 5a-k showed more potent anti-Candida activities than fluconazole.\r\nCompounds 7 and 8 revealed significant anti-Candida albicans activity and were able to effectively satisfy the\r\nproposed pharmacophore geometry, using the energy accessible conformers (Econf < 20 kcal/mol).
Loading....